AGP Executive Report

Suicide & justice in Iceland: In a new Sjónvarp Símans Premium true-crime interview, Ming Ting Mancel says she “couldn’t kill myself” and asked her husband to do it; she was sentenced to 12 years for killing her daughter at Reykjavík’s Edition hotel in June 2025, with the case framed around a plan to die together. Cardiometabolic health in Europe (incl. Iceland): JACARDI, a major EU4Health-backed joint action involving 18 EU countries plus Norway, Iceland and Ukraine, is pushing earlier prevention and better reach for cardiovascular disease and diabetes care. Rare disease treatment: The European Commission granted marketing authorisation for Nezglyal (leriglitazone) for early intervention in male childhood cerebral adrenoleukodystrophy (cALD), the first pharmacological option approved in the EU for this stage. Environmental health concern: Iceland toxicologist Oddný Ragnarsdóttir highlights PFAS “forever chemicals” as a possible skin exposure route, linking concerns to immune, liver and metabolic health. Diabetes research: A Norway study presented at EASD reports an 11% rise in type 1 diabetes incidence in young children after rotavirus vaccine rollout, while secondary analyses suggest the vaccine likely isn’t the cause. MS support: Oculis is partnering with the National Multiple Sclerosis Society to back its Campaign to End MS, focusing on vision and accelerating research and access to care. Public health safety: Nunavut health officials report suspected avian flu in 27 harvested birds near Iqaluit and stress basic food and handling precautions.

Diabetes & Vaccines: A Norway study presented at EASD reports an 11% rise in type 1 diabetes incidence in children aged 0.5–5 after rotavirus vaccine rollout in 2014, though researchers say the vaccine is likely not the cause. Cardiometabolic Prevention: EU-backed JACARDI work (including Iceland) is pushing earlier risk detection and better prevention for cardiovascular disease and diabetes across 18 EU countries plus Norway and Ukraine. Rare Disease Treatment: Nezglyal (leriglitazone) has received EU marketing authorisation for early intervention in male childhood cerebral adrenoleukodystrophy (ages 2–12), the first pharmacological option for this aggressive condition. Chemical Exposure: Experts warn PFAS “forever chemicals” may also enter the body through skin exposure, not just food and water, with possible links to immune, liver, and skin effects. Public Health in the Arctic: Nunavut health authorities suspect avian flu in 27 harvested birds near Iqaluit; they say human risk is low and recommend strict food-safety and handling precautions. Safe Abortion Access: Governments including Iceland reaffirm calls for safe, timely, affordable abortion care and warn restrictive laws increase harm. Health & Wellness in Iceland: Iceland’s geothermal heating remains a standout model—about 90% of homes rely on it—highlighting resilience lessons as energy prices and geopolitics stay in focus.

EU rare-disease breakthrough: The European Commission has granted marketing authorisation for Nezglyal (leriglitazone) under exceptional circumstances as the first EU pharmacological option for early intervention in male childhood cerebral adrenoleukodystrophy (cALD) ages 2–12 with Gd-negative brain lesions, aiming to halt irreversible neurodegeneration earlier than stem-cell transplant. Public health risk reminder: A University of Iceland toxicologist says PFAS “forever chemicals” may also enter the body through skin, not just food and water, raising concerns for immune, liver and skin effects. MS community push: Oculis is partnering with the National Multiple Sclerosis Society on its Campaign to End MS, focusing on vision and accelerating research and access to care. Care access & eligibility: The UK published guidance on indefinite leave to remain for bereaved foreign nationals, including requirements tied to the deceased partner’s status and the applicant’s visa history. Workforce strain in healthcare: Ireland plans to temporarily relax the 50:50 non-EEA hiring rule to ease staffing shortages in nursing homes, home-care and disability services. Health equity message: Governments including Iceland backed a statement for International Safe Abortion Day, urging access to safe, timely and affordable abortion care.

Neuro-ophthalmology biotech update: Oculis said director Lionel Carnot is resigning from its board, effective immediately, as the company moves into its next growth stage—an item worth watching for patients and investors in eye and brain-related sight disorders. Safe abortion access: Denmark, Estonia, Finland, France, Iceland and others backed International Safe Abortion Day with a call for laws that enable safe, timely, affordable care and warn restrictive rules raise maternal harm. HIV and aging care shift: A new look at “aging with HIV” highlights how modern ART is changing needs, with older patients facing more chronic conditions and requiring more targeted, age-aware care. Healthcare staffing pressure: Ireland plans to relax the “50:50 rule” limiting non-EEA workers to tackle shortages in nursing homes, home-care and disability services. Wound care innovation from Iceland-linked biotech: Kerecis launched “Compact,” a new fish-skin platform designed to reduce waste and simplify application for deep wounds. Longevity science angle: A roundup on extremely long-lived species—including an Iceland-named ocean clam and “immortal jellyfish”—spotlights what researchers hope to learn about aging and disease resistance.

Healthcare Workforce: Ireland is temporarily relaxing the “50:50 rule” that limits non-EEA workers to half of a healthcare employer’s staff, aiming to ease shortages in nursing homes, home-care and disability services. Rare Disease Treatment: The European Commission granted marketing authorization for Neuren’s Rett syndrome therapy (trofinetide/DAYBU), with coverage including Iceland, Norway and Liechtenstein—opening a new chapter for access to a first-in-class option. Wound Care Innovation: Kerecis launched “Compact,” a compressed fish-skin platform designed to reduce waste and make deep-wound application easier, targeting complex defects and irregular wound shapes. Mental Health & Therapy: Equine-assisted psychotherapy may help clinicians too, with research and practitioner interviews describing “horse time” as a way to stay present and reduce therapist stress. Public Health & Aging: New discussion highlights how HIV care needs are changing as people with HIV live longer, with age-related conditions and chronic inflammation reshaping clinical priorities. Digital Wellbeing: A new book argues screen-based social life can weaken empathy and human connection, pointing to brain and social effects of reduced face-to-face interaction. Community Health & Access: A Safe Abortion Day statement from multiple European governments—including Iceland—urges laws that protect access to safe, timely abortion care. Health Tech Funding (Europe): A weekly roundup reports major European healthtech investment, with AI and healthtech among the top funded sectors.

Safe Abortion Day Statement: Denmark, Estonia, Finland, Iceland and others backed International Safe Abortion Day with a call for laws that protect access to safe, timely and affordable abortion care, warning restrictive rules raise maternal harm and violate rights. Healthcare Staffing Pressure: Ireland is set to relax the “50:50 rule” that limits non-EEA workers in healthcare, aiming to ease shortages in nursing homes, home-care and disability services while training more staff. Rare Disease Treatment in Europe: The European Commission granted marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative condition. Wound Care Innovation (Iceland-linked company): Kerecis launched Compact, a new fish-skin platform designed to reduce waste and simplify application for deep wound defects, including tunneling and irregular geometries. Mental Health & Caregiving Trends: A report highlights equine-assisted psychotherapy helping not only patients but also therapists by improving presence and reducing stress. Digital Life & Loneliness: Researchers warn that screen-based communication can weaken empathy and social connection, reshaping how people relate. Local Health & Safety: A boy was injured by a discarded syringe at a Reykjavík elementary school, raising concerns about community safety. Health-Adjacent Society: A new happiness ranking puts Iceland second in the World Happiness Report, while Europe leads on closing the gender gap in health and survival.

Healthcare Staffing: Ireland is temporarily relaxing the “50:50 rule” limiting non-EEA workers to half of a healthcare workforce to ease critical staff shortages, especially in nursing homes, home-care and disability services. Rare Disease Treatment: The European Commission granted marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved in the EU for childhood cerebral adrenoleukodystrophy (cALD) in eligible patients. Wound Care Innovation: Kerecis launched Compact, a new compressed fish-skin platform designed to reduce waste and simplify handling for deep wounds and irregular wound shapes. Mental Health & Therapy Practice: Equine-assisted psychotherapy is being highlighted for helping not just patients but also therapists stay present and regulate stress during sessions. Digital Wellbeing: A new book argues that heavy screen-based social life can weaken face-to-face connection and empathy, with researchers pointing to brain and bonding differences. Local Health Safety: A boy was injured by a discarded syringe at a Reykjavík elementary school, raising concerns about community safety and prevention. Health-Adjacent Wellness: A “Disgusting Food Museum” opens in Hong Kong featuring Iceland’s hákarl among other unusual foods—more culture than care, but still a wellness-travel talking point.

New treatment for rare brain disease: The European Commission has granted marketing authorization for NEZGLYAL® (leriglitazone) for male cerebral adrenoleukodystrophy (cALD) patients aged 2–12 with Gd-negative brain lesions, the first pharmacological option approved in the EU, with an expected first launch in Germany by year-end. Wound-healing innovation: Kerecis launched Compact, a new compressed fish-skin platform designed to reduce waste and simplify application for deep, tunneling, and irregular wound defects. Mental health and care practice: A report on equine-assisted psychotherapy highlights how working with horses can help both patients and therapists by improving presence, emotional regulation, and stress reduction. Digital life and loneliness: Researchers warn that heavy screen-based socializing can weaken empathy and real-world connection, with face-to-face interaction linked to stronger brain synchrony. Public health watch: Iceland’s wider Nordic context includes renewed concern from health officials about energy drink use among teenagers. Local safety note: A boy was injured by a discarded syringe at a Reykjavík elementary school, raising urgent questions about safe disposal and prevention.

New treatment for rare brain disease: The European Commission granted marketing authorization for NEZGLYAL® (leriglitazone) for male cerebral adrenoleukodystrophy (cALD) patients aged 2–12 with Gd-negative brain lesions, the first pharmacological option in the EU for early intervention. Mental health practice insight: A new report highlights how equine-assisted psychotherapy may help not just patients but also therapists, with horses encouraging clinicians to stay more present and emotionally regulated. Screen use and loneliness: Researchers warn that heavy digital screen use can reshape social life and reduce face-to-face connection, potentially increasing loneliness. Gender gap data: Europe is again leading on closing the global gender gap, with near parity in education and health and survival—but full equality is still decades away. Health-linked community event: A large Pink Power Run 3.0 in Hyderabad drew about 35,000 people for breast cancer awareness, prevention and early detection. Iceland angle in global news: Iceland is mentioned in multiple international health and wellness contexts, including happiness rankings and conservation-related programming.

Rare disease drug approval: The European Commission has granted marketing authorization for NEZGLYAL® (leriglitazone) for childhood cerebral adrenoleukodystrophy (cALD) in male patients aged 2–12 with Gd-negative brain lesions—the first pharmacological option approved in the EU, with launches expected in Germany by year-end. Health security alert: Researchers say a new ransomware operation called Galago is emerging with claimed links to Panzer, after monitoring an Iceland-related healthcare organization claim—raising concerns for hospitals and clinics even before any confirmed victim list is published. Local health incident: A boy was injured by a discarded syringe at a Reykjavík elementary school, highlighting ongoing public safety and harm-reduction needs around sharps. Wellbeing & prevention: A large Pink Power Run 3.0 in Hyderabad drew about 35,000 people for breast cancer awareness, emphasizing prevention and early detection. Health innovation diplomacy: Minnesota Gov. Tim Walz’s trade mission to Denmark, Sweden and Iceland spotlights partnerships in healthcare innovation alongside clean tech and agriculture.

New Treatment for Rare Brain Disease: The European Commission has granted marketing authorization for NEZGLYAL® (leriglitazone) for male cerebral adrenoleukodystrophy (cALD) patients aged 2–12 with Gadolinium-negative brain lesions—described as the first pharmacological option for early intervention in the EU. Health & Safety in Schools: A boy was injured by a discarded syringe at Reykjavík Elementary School, renewing attention on safe disposal and prevention. Mental Wellbeing & Community: A new employee spotlight highlights Domestic Violence Awareness Month work in Iceland’s wider community context, focusing on prevention, survivor support, and accountability. Public Health Data & Risk: Nordic health officials sound the alarm over energy drink dependency among Swedish teenagers, pointing to growing concerns about youth consumption. Health, Climate & Resilience: UN-backed efforts to expand global ocean observation were launched at the UN General Assembly, linking better monitoring to safer navigation, weather forecasting, and coastal resilience. Wellbeing Rankings: Iceland ranks second in the World Happiness Report 2025, with Finland first—useful context for how quality of life is measured over multiple years.

UN Gaza/UNGA Clash: At the UN General Assembly, leaders sparred over Gaza’s devastation and the future of a Palestinian state, with debate turning to arms embargoes, sanctions, and settlement trade restrictions. Rare disease drug approval: The European Commission granted marketing authorization for NEZGLYAL® (leriglitazone), the first EU pharmacological treatment for childhood cerebral adrenoleukodystrophy (cALD) in eligible patients, with launches expected to begin in Germany. Rett syndrome market access: Neuren’s Rett syndrome treatment (trofinetide/Daybue) received EU-wide authorization, and the company is now focused on converting approval into first commercial sales across Iceland, Liechtenstein, and Norway too. Health cyber risk: Researchers flagged a new ransomware operation, Galago, with claimed links to Panzer and an alleged earlier hit involving an Iceland-based healthcare organization—still unconfirmed, but a clear warning for clinics. Public health basics: A guide on “silent heart attacks” highlights that many heart attacks have mild or no symptoms, yet still cause lasting damage. Local school incident: A boy was injured by a discarded syringe at Reykjavík Elementary School, underscoring ongoing safety and waste-disposal concerns.

Rare disease breakthrough: The European Commission has granted marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment in the EU for cerebral adrenoleukodystrophy (cALD) in male patients aged 2–12 with Gadolinium-negative brain lesions, with an expected first launch in Germany by year-end. Local health & safety: A report flags a new ransomware operation, “Galago,” linked to Panzer, with researchers noting an alleged Icelandic healthcare compromise claim but no independently verified victim disruption yet—worth watching for clinics and hospitals. Heart health awareness: The American Heart Association highlights “silent heart attacks,” which can cause lasting heart damage without obvious symptoms, stressing that not all heart attacks feel like the classic crushing chest pain. Public health context: A World Economic Forum update shows South Asia still far from gender parity, with economic and political gaps affecting health and survival outcomes. Iceland angle: Iceland is mentioned in multiple international health-adjacent items, including EU drug access coverage (including Iceland) and ongoing Arctic/High North activity that can affect emergency planning and health logistics.

Rett & cALD Drug News: The European Commission has cleared Neuraxpharm’s NEZGLYAL® (leriglitazone) for childhood cerebral adrenoleukodystrophy (male patients, ages 2–12, Gd-negative brain lesions), the first EU pharmacological option for early intervention. Biotech Sales Watch: Neuren Pharmaceuticals is also moving from last month’s EU Rett syndrome approval toward first commercial sales across the EU plus Iceland, Liechtenstein and Norway. Heart Attack Awareness: A new health explainer highlights “silent” heart attacks—often with mild or no symptoms—that still cause lasting heart damage. Local Harm Reduction: In Reykjavík, a boy was injured by a discarded syringe at Laugarnesskóli elementary school; the report points to Iceland’s needle exchange funding increase and Red Cross harm-reduction services. Cybersecurity for Health: Researchers warn about the emerging Galago ransomware operation, including claims tied to Panzer, with an earlier alert involving an Iceland-based healthcare organization. GBV Awareness: October’s Domestic Violence Awareness Month spotlight focuses on funding community work to prevent gender-based violence and support survivors.

Arctic Health & Safety: A boy was injured by a discarded syringe at a Reykjavík elementary school, prompting renewed attention on harm reduction and low-threshold addiction services, including the Red Cross needle exchange funding boost. Rare Disease Breakthrough: The European Commission granted marketing authorisation for NEZGLYAL® (leriglitazone) for childhood cerebral adrenoleukodystrophy (cALD), the first EU pharmacological treatment for eligible male patients. Cancer Care Update: EU regulators also issued positive CHMP opinions for perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer (MIBC), signaling potential expanded treatment options. Heart Health Awareness: A reminder that “silent” heart attacks can happen with little or no symptoms, yet still cause lasting damage—worth knowing for early risk recognition. Wellness & Nutrition: Nordic health officials sounded alarms over energy drinks, adding pressure for safer choices among young people. Community & Food Systems: A Nordic cook-off in Washington highlighted Nordic food traditions—an indirect nudge toward healthier eating habits through culture.

Needle safety in Reykjavík schools: A boy was injured after finding a used syringe on school grounds at Laugarnesskóli elementary in central Reykjavík, prompting reminders of harm-reduction efforts. Iceland’s Ministry of Health previously boosted funding for the Red Cross needle exchange Frú Ragnheiður (including the Ylja site) to reduce risks linked to discarded syringes. Health tech and treatment advances: Iceland-based Kerecis’ cod-skin grafts are being highlighted for wound healing, including for diabetic foot wounds and burn trauma, as researchers and clinicians look for better ways to support tissue repair. Cancer care in Europe: New EU CHMP opinions support immunotherapy combinations for muscle-invasive bladder cancer (including perioperative enfortumab vedotin plus pembrolizumab), pointing to continued momentum in oncology options. Heart attack awareness: A reminder that “silent” heart attacks can happen with little or no symptoms—still causing lasting damage—underscores the need for awareness beyond classic chest pain. Cyber risk to healthcare: Researchers flagged a new ransomware operation, Galago, with claimed links to Panzer; while not yet confirmed in victims, the report stresses the risk to healthcare organizations.